Free Reports

Free Reports

Pricing

About us

Contact us

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Resources

Links

Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

Free Reports

Free Reports

Pricing

About us

Contact us

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Resources

Links

Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

Home
Biotech & Pharmaceuticals
Has Neuren Pharmaceuticals' (NEU) share price bottomed out?